• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1997년도 제13회 학술발표회 논문개요집
• /
• pp.169-172
• /
• 1997

MgO dielectric pprotection layer is ppreppared by R.F. reactive magnetron spputtering with Mg target under various conditions of spputtering ppressure, time and substrate tempperature. Discharge characteristics of ppDpp is also studied as a pparameter of MgO pprepparation conditions. As the working ppressure and substrate tempperature was increase, the discharge voltage was decreased. Two kinds of MgO ppreppared both spputtering and E-beam methods were stable after annealing at 35$0^{\circ}C$ for 120min. discharge voltage under 3 mixed gas(He+Xe0.2%+Ne30%) was V=130V, V=102V and ${\gamma}$ coefficient was twiced as much as that of dielectric layer.

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1999년도 제16회 학술발표회 논문개요집
• /
• pp.175-175
• /
• 1999

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1999년도 제16회 학술발표회 논문개요집
• /
• pp.178-178
• /
• 1999

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1999년도 제16회 학술발표회 논문개요집
• /
• pp.180-180
• /
• 1999

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1999년도 제16회 학술발표회 논문개요집
• /
• pp.185-185
• /
• 1999

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1998년도 제14회 학술발표회 논문개요집
• /
• pp.183-183
• /
• 1998

• 한국진공학회:학술대회논문집
• /
• 한국진공학회 1999년도 제16회 학술발표회 논문개요집
• /
• pp.186-186
• /
• 1999

• 폴리머
• /
• 제29권6호
• /
• pp.565-570
• /
• 2005

용융 점도 조절에 의한 나일론6(N6)의 melt impregnation공정에서의 용융가공 특성에 대하여 고찰하여 보았다. N6의 용융 점도를 조절하기 위하여 calcium stearate(CaST)를 윤활제로 사용한 결과, 1 wt$\%$의 윤활제의 첨가에 의하여 용융 점도가 감소함을 알 수 있었다. 아울러 폴리카프로락톤(PCL)을 N6에 반응 용융 블렌딩하여 N6의 용융 점도를 낮출 수 있었으며 phenyl phosphite(PP)와 diphenyl phosphite(DPP)를 첨가하여 블렌딩 시 상호에스테르 교환반응을 증가시켜 추가적인 용융 점도 감소를 확인하였다. 이러한 방법들은 N6의 고온 가공의 문제점으로 지적되는 열안정성 저하를 최소화하면서 melt impregnation 공정에서 필수적인 저점도 가공을 가능하게 할 수 있을 것으로 사료된다.

• 대한한방내과학회지
• /
• 제42권1호
• /
• pp.40-52
• /
• 2021

Objective: This study was conducted to investigate the hypoglycemic effect and safety of Ojeok-san in patients with type 2 Diabetes Mellitus. Methods: We investigated type 2 diabetes mellitus patients at Kyung-Hee University Korean Medical Hospital who were administered Ojeok-san for at least one day between January 2012 and September 2020, basal characteristics and laboratory tests were reviewed retrospectively. The hypoglycemic effect of Ojeok-san was assessed by comparing fasting blood sugar (FBS) and two hours post-prandial plasma glucose (PP2) levels from before and after taking Ojeok-san. Subgroup analyses were conducted according to baseline hypoglycemic treatments and glycated hemoglobin levels (< or ≥6.5%). The safety of Ojeok-san was assessed by comparing levels of aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, blood urea nitrogen, and creatinine. Results: After Ojeok-san administration, FBS and PP2 were significantly reduced to an average of 14.33 mg/dL and 27.67 mg/dL respectively. In the subgroup analysis, PP2 in patients receiving metformin mono therapy was significantly reduced to 28.67 mg/dL, and those receiving a dual therapy of metformin and DPP-4 inhibitor, it was significantly reduced to 32.33 mg/dL. In patients with glycated hemoglobin of lower than 6.5%, FBS was significantly reduced to 12.20 mg/dL, and both FBS and PP2 were significantly reduced, to 15.50 mg/dL and 40.00 mg/dL, respectively, in those with glycated hemoglobin levels of more than 6.5%. The safety profile showed no significant difference after Ojeok-san administration. Conclusions: Ojeok-san has significant hypoglycemic effects in patients with type 2 diabetes mellitus who are also taking hypoglycemic agents.